Recombinant erythropoietin biosimilar - Lupin

Drug Profile

Recombinant erythropoietin biosimilar - Lupin

Alternative Names: Epocept; Erythropoietin biosimilar - Lupin; rHuEPO biosimilar - Lupin

Latest Information Update: 08 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lupin
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 07 May 2014 Launched for Anaemia (in adult patients with chronic renal failure) in India (IV) before May 2014
  • 07 May 2014 Launched for Anaemia (in adult patients with chronic renal failure) in India (SC) before May 2014
  • 17 Aug 2011 Registered for Anaemia (in adult patients with chronic renal failure) in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top